Brief: Urogen Pharma Announces Update On The Phase 2 Trial Of An RTgel Hydrogel Formulation In Combination With Botox

UroGen Pharma

27/08/2020 13:08

Aug 27 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN PHARMA ANNOUNCES UPDATE ON THE PHASE 2 TRIAL OF AN
RTGEL™
HYDROGEL FORMULATION IN COMBINATION WITH BOTOX®
(ONABOTULINUMTOXINA) INTRAVESICAL INSTILLATION FOR OVERACTIVE
BLADDER AND URINARY INCONTINENCE
    * UROGEN PHARMA LTD - TRIAL DID NOT MEET PRIMARY ENDPOINT
BELIEVED
TO BE RESULT OF BOTOX NOT EFFECTIVELY PERMEATING UROTHELIUM
    * UROGEN PHARMA LTD - TRIAL DID NOT MEET PRIMARY ENDPOINT
BELIEVED
TO BE RESULT OF BOTOX NOT EFFECTIVELY PERMEATING UROTHELIUM
    * UROGEN PHARMA LTD - RTGEL DELIVERED TREATMENT TO BLADDER
AS
EXPECTED WITH DWELL TIME OF UP TO 10 HOURS
    * UROGEN PHARMA LTD - UROGEN AND ABBVIE WILL CONTINUE TO
EXPLORE
USE OF RTGEL HYDROGEL FORMULATION WITH ABBVIE'S PORTFOLIO OF
TOXIN PROTEINS
    * UROGEN PHARMA LTD - NO IMPACT TO UROGEN'S CURRENT
FINANCIAL
POSITION

Source text for Eikon:  ID:nBwbW4zW4a 
Further company coverage:  UR8.F 

 ((Reuters.Briefs@thomsonreuters.com;))